We also demonstrated that serum IFN activity correlated with disease activity in treatment-naive SLE patients (Fig. 4A) and that serum IFN activity at baseline decreased along with a decrease in disease activity after induction and maintenance therapy (Fig. 4B). The gene discussed is IFNA1; the disease is systemic lupus erythematosus.